-+ 0.00%
-+ 0.00%
-+ 0.00%

Nexentis Subsidiary MitoCareX Orders Molecules for Planned In-Vitro Testing

PUBT·11/17/2026 13:07:27
Listen to the news
Nexentis Subsidiary MitoCareX Orders Molecules for Planned In-Vitro Testing
  • Nexentis' wholly owned subsidiary MitoCareX Bio ordered molecules for planned in vitro evaluation following additional computational prioritization.
  • The selection follows initial computational screening under its drug-discovery initiative with Boltz, announced Oct. 29, 2026.
  • Molecules have not yet arrived; in vitro testing has not begun.
  • Computational predictions remain experimentally unvalidated; molecule selection does not establish biological activity or suitability for further development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170803PRIMZONEFULLFEED9879359) on November 17, 2026, and is solely responsible for the information contained therein.